Abstract submission for EANO 2025 is CLOSED!
Authors of submitted abstracts will be notified about the status of their submission and the final assignment (oral presentation or poster) via email by June 25, 2025.
GENERAL INFORMATION ON ABSTRACT SUBMISSION
- EANO accepts regular, encore or trial in progress abstracts.
- Abstracts containing no results or structure will be rejected.
- Abstracts with the obvious goal of advertising corporate products or services, will be rejected.
- All submitted abstracts will be anonymised and reviewed by an independent review panel coordinated by the Scientific Committee.
- Accepted abstracts will be published on the website of Neuro-Oncology beginning of October 2025.
- There will not be a printed abstract book.
- The embargo for abstracts submitted to EANO 2025 will lift on October 2, 2025.
REGISTRATION
At least the presenting author of an abstract is obliged to register and pay the congress registration fee within 2 weeks (but not later than July 31, 2025) after notification on acceptance. In the event of non-fulfillment, the abstract will be withdrawn by the organisers.
SUBMISSION TOPICS
01. Tumour cell biology, heterogeneity and plasticity
02. Microenvironment
03. Imaging
04. Computational neuro-oncology
05. Advanced diagnostics and biomarkers
06. Neurocognition and connectome
07. Neurosurgery, drug delivery and advanced techniques
08. Immunotherapy
09. Radiation
10. Pediatric brain tumors
11. Brain metastasis and leptomeningeal disease
12. Adult glioma
13. Meningioma
14. Rare CNS tumors
15. Palliative and supportive care/QoL
16. Public cancer policies and patient involvement
17. Clinical neuro-oncology
18. Preclinical neuro-oncology
SUPPORT
For support during the submission process and any other questions, please send an email to eano-meetings@eano.eu or call +43 1 405 13 83 14 between 9.00 – 17.00 hrs Central European Time.
Simultaneous Publication
We are aiming to publish full manuscripts of selected major content simultaneously with the oral presentation at the EANO Meeting in Neuro-Oncology.
Please indicate your preference for your abstract to be evaluated for this opportunity by using the appropriate tick box during the submission process (SUBMISSION STEP 8: MORE INFORMATION).